<SEC-DOCUMENT>0001178913-24-002405.txt : 20240805
<SEC-HEADER>0001178913-24-002405.hdr.sgml : 20240805
<ACCEPTANCE-DATETIME>20240805085319
ACCESSION NUMBER:		0001178913-24-002405
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20240805
FILED AS OF DATE:		20240805
DATE AS OF CHANGE:		20240805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MediWound Ltd.
		CENTRAL INDEX KEY:			0001593984
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36349
		FILM NUMBER:		241173248

	BUSINESS ADDRESS:	
		STREET 1:		42 HAYARKON STREET
		CITY:			YAVNE
		STATE:			L3
		ZIP:			8122745
		BUSINESS PHONE:		97289324010

	MAIL ADDRESS:	
		STREET 1:		42 HAYARKON STREET
		CITY:			YAVNE
		STATE:			L3
		ZIP:			8122745
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2431776.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: zk-global
         Document created using Broadridge PROfile 24.6.1.5240
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div><br>
  </div>
  <div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Washington, D.C.&#160; 20549<br>
      ______________________</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">FORM 6-K</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">REPORT&#160;OF FOREIGN PRIVATE ISSUER</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Pursuant to Rule 13a-16 or 15d-16 of the<br>
      Securities Exchange Act of 1934</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">For the month of August 2024</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Commission File Number: 001-36349</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25;"><font style="font-size: 16pt; font-family: 'Times New Roman',Times,serif;"><u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></font><font style="font-size: 16pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u>MediWound
          Ltd.&#160;</u></font><font style="font-size: 16pt; font-family: 'Times New Roman',Times,serif;"><u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></font><br>
      (Translation of registrant&#8217;s name into English)</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">42 Hayarkon Street</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Yavne, 8122745 Israel</div>
    <div style="text-align: center; line-height: 1.25;">&#160;(Address of principal executive offices)</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center;"><font style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Form 20-F&#160; &#9746;
        &#160;&#160;&#160;&#160;&#160;&#160;&#160; Form 40-F &#9744;</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&#160;&#160; __</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&#160;&#160; __</div>
    <div style="line-height: 1.25">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">EXPLANATORY NOTE</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On August 5, 2024, MediWound Ltd. (the &#8220;Company&#8221;) issued a press release entitled &#8220;MediWound announces positive results from the U.S. NexoBrid<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> Expanded Access Protocol
      (NEXT)&#8221;. A copy of this press release is attached to this Report of Foreign Private Issuer on Form 6-K (this &#8220;Form 6-K&#8221;) as Exhibit 99.1.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The content of this report on Form 6-K (including the information contained in Exhibit 99.1, but excluding quotes of senior management of the Company), is hereby incorporated by
      reference into the Company&#8217;s Registration Statements on Form S-8 filed with the SEC on April 28, 2014, March 24, 2016, March 19, 2018, March 25, 2019, February 25, 2020, May 15, 2021 August 9, 2022 and August 15, 2023&#160;(Registration Nos. No.
      333-195517, 333-210375, 333-223767, 333-230487, 333-236635, 333-255784, 333-266697 and 333-273997, respectively) and on Form F-3 filed with the SEC on May 25, 2022 and March 31, 2023 (Registration Nos. 333-265203 and 333-268297, respectively).</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">SIGNATURE</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" border="0" id="z775e398259904366887b0bc2abb95bec" style="background-color: #FFFFFF; letter-spacing: normal; width: 100%; word-spacing: 0px; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-transform: none;">

          <tr>
            <td style="width: 50%;">
              <div>
                <div style="text-align: left; line-height: 1.25;"><font style="color: rgb(0, 0, 0);">Date: </font>August 5, 2024</div>
              </div>
            </td>
            <td style="width: 50%;">
              <div style="color: rgb(0, 0, 0);">MEDIWOUND LTD.</div>
              <div><font style="color: rgb(0, 0, 0);"><br>
                </font></div>
              <div>
                <div style="text-align: left; line-height: 1.25; color: rgb(0, 0, 0);">By:&#160;&#160;<u>/s/&#160;</u><u>Hani Luxenburg</u>&#160;&#160;&#160;&#160;&#160;&#160;</div>
                <div style="text-align: left; line-height: 1.25; color: rgb(0, 0, 0);">Name:&#160; Hani Luxenburg</div>
                <div style="text-align: left; line-height: 1.25; color: rgb(0, 0, 0);">Title:&#160; &#160; Chief Financial Officer</div>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">EXHIBIT INDEX</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">The following exhibit is filed as part of this Form 6-K:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" border="0" id="zadc78ca61fe34effb7b085b54603f71a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 7%;">
              <div>
                <div style="text-align: left; line-height: 1.25;"><u>Exhibit</u><br>
                </div>
              </div>
            </td>
            <td style="width: 1%;">
              <div>&#160;</div>
            </td>
            <td style="width: 92%;">
              <div><u>Description</u> <br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 7%;">
              <div>&#160;</div>
            </td>
            <td style="width: 1%;">
              <div>&#160;</div>
            </td>
            <td style="width: 92%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 7%;">
              <div><a href="exhibit_99-1.htm">99.1 <br>
                </a> </div>
            </td>
            <td style="width: 1%;"><br>
            </td>
            <td style="width: 92%;">
              <div>
                <div><a href="exhibit_99-1.htm">Press release dated August 5, 2024 entitled &#8220;MediWound announces positive results from the U.S. NexoBrid<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> Expanded Access
                    Protocol (NEXT)&#8221;.</a></div>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: zk-global
         Document created using Broadridge PROfile 24.6.1.5240
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div style="text-align: right;"><u><font style="font-weight: bold;">Exhibit 99.1</font></u><br>
  </div>
  <div>
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">MediWound Announces Positive Results from the U.S. NexoBrid<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup></div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"></sup> Expanded Access Protocol (NEXT)</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing</div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;"> Surgical Procedures for Burn Patients</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">YAVNE, Israel, August 5, 2024</font> --
      MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced the positive results of the NEXT&#8212;an Expanded Access Protocol. NEXT, initiated in 2019, aimed to ensure the continuous
      availability of NexoBrid<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> in burn centers until its commercialization. This program successfully maintained physician expertise, provided burn victims with ongoing access to this life-saving treatment, and facilitated the accumulation of
      real-world safety and clinical data for NexoBrid.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Jeremy Goverman, MD, FACS, Associate Professor of Surgery at Harvard Medical School, commented, &#8220;The NEXT results reaffirm the
      significant benefits of NexoBrid in managing severe burns. This enzymatic debridement agent accelerates the debridement process and reduces the need for surgical interventions, ultimately enhancing patient outcomes. The findings from NEXT are
      consistent with data from the DETECT and CIDS Phase III trials, reinforcing the critical role that NexoBrid should play in standard burn care protocols.&#8221;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">NEXT, an open-label, single-arm treatment protocol was conducted at 29 burn centers across the U.S. 239 patients, including 215 adults
      and 24 children, with deep partial and full-thickness thermal burns covering up to 30% of the total body surface area (TBSA) were treated with NexoBrid.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Key Results of the NEXT Protocol Include:</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zb11811501a5a40d7836cf542c212e0a5" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">Efficacy</font> (findings were consistent with Phase III studies
              results):</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z2a33a42fe83445029edd40aca98afbe7" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 54pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">o</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>94.9% of adults and 100% of children achieved complete debridement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zea58cf52b9b04a689ba93a469e7b685b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 54pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">o</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Only 4.2% of adults required surgical excision for eschar removal after NexoBrid treatment, and none in the pediatric group.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z6ec09ea47c45480faa07ccb8a633b100" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 54pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">o</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The mean (&#177; SD) percent of wound area surgically excised for adults was 3.6% (&#177;18.33), and 0% for children.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zf1be3d06cc1f4897818fc25911f9e6a4" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 54pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">o</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The time to complete eschar removal was less than one day for both adults and children.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z938047cf88dc416f9ed38db28e587e95" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-weight: bold;">Healing and Hospitalization:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z253b4df9941e4d9581f95471aaae90ac" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 54pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">o</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The median time to wound closure was 22 days (95% CI: 22, 23) for adults and 28 days (95% CI: 18, 32) for children.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z9a0d71ebf27b4c599c2b170ac9e19b7f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 54pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">o</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The median time of hospitalization duration was 10 days (95% CI: 8, 11) for adults and 10 days (95% CI: 5, 14) for children.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zc9f741fae561436db8ee0aaff11db554" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">Safety:</font> The safety data was consistent with the established
              safety profile of NexoBrid, and no new safety concerns were identified by the Data Safety and Monitoring Board (DSMB).</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z73ae65b456104ef999b3fa60af1a6319" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">Benefit-Risk Ratio:</font> The overall benefit-to-risk ratio of NexoBrid
              treatment remains favorable.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About NexoBrid</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">NexoBrid<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is a topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in
        patients with deep partial and/or full-thickness thermal burns without harming viable tissue. NexoBrid<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is approved in over 40 countries, including the United States, European Union, and Japan. It has been designated as an orphan
        biologic drug in all these territories.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">NexoBrid development has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services;
        Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract HHSO100201500035C. This contract provided funding and technical support for the pivotal U.S. Phase 3 clinical
        study (DETECT), the randomized, controlled pivotal clinical trial for use in the pediatric population (CIDS), the marketing approval registration process for NexoBrid as well as its procurement and availability under the expanded access protocol
        (NEXT). Additional projects for evaluation of NexoBrid funded under the BARDA contract include establishment of a pre-emergency use data package and development of the health economic model to evaluate the cost savings impact to enable market
        adoption in the United States.</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About&#160;MediWound</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The
      Company specializes in the development, production and commercialization of rapid and effective biologics that improve existing standards of care and patient experiences, while reducing costs and unnecessary surgeries.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">MediWound&#8217;s first drug, NexoBrid<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, is an FDA and EMA-approved orphan biologic for eschar removal in deep partial-thickness
      and/or full-thickness thermal burns, which can significantly reduce surgical interventions. Utilizing the same core biotherapeutic enzymatic platform technology, MediWound has developed a strong R&amp;D pipeline, including the company&#8217;s lead drug
      under development, EscharEx<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>. EscharEx is a Phase III-ready biologic for the debridement of chronic wounds, offering significant potential advantages over the dominant $360+ million product and an opportunity to expand the market.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">For more information visit <u>www.mediwound.com</u>
      and follow the Company on <u>LinkedIn</u>.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Cautionary Note Regarding Forward-Looking Statements</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-style: italic;">MediWound&#160;cautions you that all
          statements other than statements of historical fact included in this press release that address activities, events, or developments that we expect,&#160;believe,&#160;or anticipate will or may occur in the future are forward-looking statements.&#160;Although we
          believe that we have a reasonable basis for the forward-looking statements contained herein, they are based on current&#160;expectations about future events affecting us and are subject to risks, assumptions,&#160;uncertainties,&#160;and factors, all of which
          are difficult to predict and many of which are beyond our control.&#160; Actual results may differ materially from those expressed or implied by the forward-looking statements in this press release.&#160; These statements are often, but are not always,
          made through the use of words or phrases such as &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;continues,&#8221; &#8220;believe,&#8221; &#8220;guidance,&#8221; &#8220;outlook,&#8221; &#8220;target,&#8221; &#8220;future,&#8221; &#8220;potential,&#8221; &#8220;goals&#8221; and similar words or phrases, or future or
          conditional verbs such as &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;may,&#8221; or similar expressions</font>. <font style="font-style: italic;">Specifically, this press release contains forward-looking statements concerning the anticipated progress, development, expectations
            and commercial potential of our products and product candidates, including NexoBrid</font><sup style="font-style: italic; vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><sub style="font-style: italic; vertical-align: bottom; line-height: 1; font-size: smaller;">.</sub><font style="font-style: italic;"> Among the factors that may cause results to be materially different from those stated herein are the inherent uncertainties associated our expectations regarding future growth, market acceptance of our products and
            product candidates; our ability to maintain adequate protection of our intellectual property; competition risks; the impact of government laws and regulations and the impact of the current global macroeconomic climate on our ability to source
            supplies for our operations or our ability or capacity to manufacture, sell and support the use of our products and product candidates in the future. These and other significant factors are discussed in greater detail in MediWound&#8217;s annual report on Form 20-F for
          the year ended&#160;December 31, 2023, filed with the&#160;Securities and Exchange Commission&#160;(&#8220;SEC&#8221;) on&#160;March 21, 2024 and Quarterly Reports on Form 6-K and other filings with the&#160;SEC&#160;from time-to-time. These forward-looking statements reflect MediWound&#8217;s
          current views as of the date hereof and&#160;MediWound&#160;undertakes, and specifically disclaims, any obligation to update any of these forward-looking statements to reflect a change in their respective views or events or circumstances that occur after
          the date of this release except as required by law.</font></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">
          <table cellspacing="0" cellpadding="0" border="0" style="width: 100%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" id="zc434eaffe31c4a6ebacd5b867e5b6461">

              <tr>
                <td style="width: 50%;">
                  <div>
                    <div style="line-height: 1.25;">
                      <div style="text-align: left; line-height: 1.25; font-weight: bold;">MediWound Contacts:</div>
                    </div>
                    <div style="text-align: justify; line-height: 1.25;">Hani Luxenburg&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
                    <div style="text-align: justify; line-height: 1.25;">Chief Financial Officer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
                    <div style="text-align: justify; line-height: 1.25;">MediWound Ltd.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
                    <div style="line-height: 1.25;">
                      <div style="text-align: left; line-height: 1.25;"><u>ir@mediwound.com</u>&#160;&#160;&#160;<br>
                        </div>
                    </div>
                  </div>
                </td>
                <td style="width: 50%;">
                  <div><br>
                    </div>
                  <div>Daniel Ferry</div>
                  <div>Managing Director</div>
                  <div>
                    <div>LifeSci Advisors, LLC</div>
                    <div><u>daniel@lifesciadvisors.com</u></div>
                  </div>
                </td>
              </tr>

          </table>
        </div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25; font-weight: bold;">Media Contact:&#160;</div>
        <div style="line-height: 1.25;">
          <div style="color: rgb(0, 0, 0); font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; line-height: 1.25;">Ellie Hanson<br>
            FINN Partners for MediWound</div>
          <div style="color: rgb(0, 0, 0); font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; line-height: 1.25;"><u>ellie.hanson@finnpartners.com</u></div>
          <div style="color: rgb(0, 0, 0); font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; line-height: 1.25;">+1-929-588-2008</div>
          <br class="Apple-interchange-newline">
        </div>
      </div>
    </div>
    <div class="BRPFPageFooter">
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">
          <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
